{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:24:02Z","timestamp":1789773842208,"version":"4.0.1"},"reference-count":24,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Radiation-induced lymphopenia (RIL) is associated with an increased risk of death in solid tumors, including rectal cancer. The aim of this study was to determine whether the sequencing of chemotherapy in total neoadjuvant treatment (TNT) for rectal cancer predicts the development of RIL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>\n                      We analyzed acute hematologic toxicity data from 53 patients who underwent TNT for locally or locoregionally advanced rectal cancer between July 2022 and April 2023. Twenty-eight patients received induction chemotherapy with capecitabine and oxaliplatin [CAPOX], and 25 received consolidation chemotherapy (6 cycles of CAPOX in both groups). The chemoradiation protocol consisted of Volumetric Modulated Arc Therapy with Simultaneous Integrated Boost Radiotherapy (VMAT-SIB RT) up to 48.4 Gy in 22 fractions, concomitantly with capecitabine twice a day (\n                      <jats:italic>lat. bis in die<\/jats:italic>\n                      , BID). The Mann-Whitney U test was performed to compare RIL between the two patient groups. Pelvic bone marrow was contoured as a non-limiting organ-at-risk to assess the received dose, and binary logistic regression was used to determine whether RIL depends on V\n                      <jats:sub>5Gy<\/jats:sub>\n                      ~V\n                      <jats:sub>42Gy<\/jats:sub>\n                      or the planning target volume (PTV) size.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-four patients (64.2%) developed RIL of any grade, which was not significantly associated with either the induction or consolidation chemotherapy TNT regimen (Wald = 3.159, p = 0.076). No significant differences were found in neutrophil counts or the neutrophil-to-lymphocyte ratio. In the logistic regression model predicting the likelihood of RIL, two variables were statistically significant: V\n                      <jats:sub>10Gy<\/jats:sub>\n                      (Wald = 4.366, p = 0.037) and V\n                      <jats:sub>30Gy<\/jats:sub>\n                      (Wald = 6.084, p = 0.014). These results indicate that V\n                      <jats:sub>10Gy<\/jats:sub>\n                      &lt; 71% and V\n                      <jats:sub>30Gy<\/jats:sub>\n                      &lt; 26.6% may reduce the likelihood of developing RIL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In our study, the sequencing of chemotherapy in TNT for rectal cancer did not predict the development of RIL. However, the incidence of RIL may be reduced by applying RT dosimetric constraints to the pelvic bone marrow.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2025-0034","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T14:18:08Z","timestamp":1750601888000},"page":"252-256","source":"Crossref","is-referenced-by-count":2,"title":["Sequencing of chemotherapy in total neoadjuvant treatment for rectal cancer does not predict radiation-induced lymphopenia"],"prefix":"10.2478","volume":"59","author":[{"given":"Miha","family":"Orazem","sequence":"first","affiliation":[{"name":"Division of Radiotherapy, Institute of Oncology Ljubljana , Ljubljana , Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaneja","family":"Velenik","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy, Institute of Oncology Ljubljana , Ljubljana , Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alojz","family":"Ihan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"},{"name":"Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"2026071215474082337_j_raon-2025-0034_ref_001","doi-asserted-by":"crossref","unstructured":"El Houat Y, Massard C, Quillien V, de Crevoisier R, Castelli J. Meta-analysis and critical review: association between radio-induced lymphopenia and overall survival in solid cancers. Adv Radiat Oncol 2022; 8: 101038. doi: 10.1016\/j.adro.2022.101038","DOI":"10.1016\/j.adro.2022.101038"},{"key":"2026071215474082337_j_raon-2025-0034_ref_002","doi-asserted-by":"crossref","unstructured":"Duque-Santana V, L\u00f3pez-Campos F, Martin-Martin M, Valero M, Zafra-Mart\u00edn J, Cou\u00f1ago F, et al. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic factors in locally advanced rectal cancer. Oncology 2023; 101: 349-57. doi: 10.1159\/000526450","DOI":"10.1159\/000526450"},{"key":"2026071215474082337_j_raon-2025-0034_ref_003","doi-asserted-by":"crossref","unstructured":"Pham TN, Coupey J, Thariat J, Valable S. Impact of circulating lymphocyte kinetics following radiotherapy on patient survival: a model-based meta-analysis. Comput Biol Med 2025; 186: 109702. doi: 10.1016\/j.comp-biomed.2025.109702","DOI":"10.1016\/j.compbiomed.2025.109702"},{"key":"2026071215474082337_j_raon-2025-0034_ref_004","doi-asserted-by":"crossref","unstructured":"Ellsworth SG. Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors. Adv Radiat Oncol 2018; 3: 512-9. doi: 10.1016\/j.adro.2018.08.014","DOI":"10.1016\/j.adro.2018.08.014"},{"key":"2026071215474082337_j_raon-2025-0034_ref_005","doi-asserted-by":"crossref","unstructured":"Prades-Sagarra E, Yaromina A, Dubois LJ. Understanding the impact of radiation-induced lymphopenia: preclinical and clinical research perspectives. Clin Transl Radiat Oncol 2024; 49: 100852. doi: 10.1016\/j.ctro.2024.100852","DOI":"10.1016\/j.ctro.2024.100852"},{"key":"2026071215474082337_j_raon-2025-0034_ref_006","doi-asserted-by":"crossref","unstructured":"Terrones-Campos C, Ledergerber B, Vogelius IR, Specht L, Helleberg M, Lundgren J. Lymphocyte count kinetics, factors associated with the end-of-radiation-therapy lymphocyte count, and risk of infection in patients with solid malignant tumors treated with curative-intent radiation therapy. Int J Radiat Oncol Biol Phys 2019; 105: 812-23. doi: 10.1016\/j.ijrobp.2019.07.013","DOI":"10.1016\/j.ijrobp.2019.07.013"},{"key":"2026071215474082337_j_raon-2025-0034_ref_007","doi-asserted-by":"crossref","unstructured":"Tuta M, Boc N, Brecelj E, Omejc M, Anderluh F, Ermenc AS, et al. Total neoadjuvant treatment of locally advanced rectal cancer with high risk factors in Slovenia. Radiol Oncol 2019; 53: 465-72. doi: 10.2478\/raon-2019-0046","DOI":"10.2478\/raon-2019-0046"},{"key":"2026071215474082337_j_raon-2025-0034_ref_008","doi-asserted-by":"crossref","unstructured":"Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer GG, Fietkau R, et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO\/ARO\/AIO-12 randomized clinical trial. JAMA Oncol 2022; 8: e215445. doi: 10.1001\/jamaoncol.2021.5445","DOI":"10.1001\/jamaoncol.2021.5445"},{"key":"2026071215474082337_j_raon-2025-0034_ref_009","doi-asserted-by":"crossref","unstructured":"Verheij FS, Omer DM, Williams H, Lin ST, Qin LX, Buckley JT, et al. Longterm results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial. J Clin Oncol 2024; 42: 500-6. doi: 10.1200\/JCO.23.01208","DOI":"10.1200\/JCO.23.01208"},{"key":"2026071215474082337_j_raon-2025-0034_ref_010","doi-asserted-by":"crossref","unstructured":"Bedrikovetski S, Traeger L, Seow W, Dudi-Venkata NN, Selva-Nayagam S, Penniment M, et al. oncological outcomes and response rate after total neoadjuvant therapy for locally advanced rectal cancer: a network metaanalysis comparing induction vs. consolidation chemotherapy vs. standard chemoradiation. Clin Colorectal Cancer 2024; 23: 326-36.e9. doi: 10.1016\/j. clcc.2024.06.001","DOI":"10.1016\/j.clcc.2024.06.001"},{"key":"2026071215474082337_j_raon-2025-0034_ref_011","doi-asserted-by":"crossref","unstructured":"Fokas E, Williams H, Diefenhardt M, Lin S, Qin LX, Piso P, et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: pooled analysis of the CAO\/ARO\/AIO-12 and the OPRA randomized phase 2 trials. Eur J Cancer 2024; 210: 114291. doi: 10.1016\/j.ejca.2024.114291","DOI":"10.1016\/j.ejca.2024.114291"},{"key":"2026071215474082337_j_raon-2025-0034_ref_012","doi-asserted-by":"crossref","unstructured":"Fokas E, Allg\u00e4uer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, et al. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO\/ARO\/AIO-12. J Clin Oncol 2019; 37: 3212-22. doi: 10.1200\/JCO.19.00308.","DOI":"10.1200\/JCO.19.00308"},{"key":"2026071215474082337_j_raon-2025-0034_ref_013","doi-asserted-by":"crossref","unstructured":"Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 2022; 40: 2546-2556. doi: 10.1200\/JCO.22.00032","DOI":"10.1200\/JCO.2022.40.16_suppl.3619"},{"key":"2026071215474082337_j_raon-2025-0034_ref_014","doi-asserted-by":"crossref","unstructured":"Verheij FS, Omer DM, Lin ST, Yuval JB, Thompson HM, Kim JK, et al. Compliance and toxicity of total neoadjuvant therapy for rectal cancer: a secondary analysis of the OPRA Trial. Int J Radiat Oncol Biol Phys 2024; 118: 115-123. doi: 10.1016\/j.ijrobp.2023.07.043","DOI":"10.1016\/j.ijrobp.2023.07.043"},{"key":"2026071215474082337_j_raon-2025-0034_ref_015","doi-asserted-by":"crossref","unstructured":"Zimmermann M, Richter A, Weick S, Exner F, Mantel F, Diefenhardt M, et al. Acute toxicities of patients with locally advanced rectal cancer treated with intensified chemoradiotherapy within the CAO\/ARO\/AIO-12 trial: comparing conventional versus VMAT planning at a single center. Sci Rep 2022; 12: 21263. doi: 10.1038\/s41598-022-25647-8","DOI":"10.1038\/s41598-022-25647-8"},{"key":"2026071215474082337_j_raon-2025-0034_ref_016","doi-asserted-by":"crossref","unstructured":"Nanos C, Koukourakis IM, Mulita A, Avgousti R, Kouloulias V, Zygogianni A, et al. Lymphopenia induced by different neoadjuvant chemo-radiotherapy schedules in patients with rectal cancer: bone marrow as an organ at risk. Curr Oncol 2024; 31: 5774-88. doi: 10.3390\/curroncol31100429","DOI":"10.3390\/curroncol31100429"},{"key":"2026071215474082337_j_raon-2025-0034_ref_017","doi-asserted-by":"crossref","unstructured":"Corbeau A, Kuipers SC, de Boer SM, Horeweg N, Hoogeman MS, Godart J, et al. Correlations between bone marrow radiation dose and hematologic toxicity in locally advanced cervical cancer patients receiving chemoradiation with cisplatin: a systematic review. Radiother Oncol 2021; 164: 128-37. doi: 10.1016\/j.radonc.2021.09.009","DOI":"10.1016\/j.radonc.2021.09.009"},{"key":"2026071215474082337_j_raon-2025-0034_ref_018","doi-asserted-by":"crossref","unstructured":"Dov\u0161ak T, Ihan A, Didanovi\u010d V, Kansky A, Ihan Hren N. Influence of surgical treatment and radiotherapy of the advanced intraoral cancers on complete blood count, body mass index, liver enzymes and leukocyte CD64 expression. Radiol Oncol 2009; 43: 282-92. doi: 10.2478\/v10019-009-0034-8","DOI":"10.2478\/v10019-009-0034-8"},{"key":"2026071215474082337_j_raon-2025-0034_ref_019","doi-asserted-by":"crossref","unstructured":"Dov\u0161ak T, Ihan A, Didanovi\u010d V, Kansky A, Verdenik M, Hren NI. Effect of surgery and radiotherapy on complete blood count, lymphocyte subsets and inflammatory response in patients with advanced oral cancer. BMC Cancer 2018; 18: 235. doi: 10.1186\/s12885-018-4136-9","DOI":"10.1186\/s12885-018-4136-9"},{"key":"2026071215474082337_j_raon-2025-0034_ref_020","doi-asserted-by":"crossref","unstructured":"Zhu J, Lian J, Xu B, Pang X, Ji S, Zhao Y, et al. Neoadjuvant immunotherapy for colorectal cancer: right regimens, right patients, right directions? Front Immunol 2023; 14: 1120684. doi: 10.3389\/fimmu.2023.1120684","DOI":"10.3389\/fimmu.2023.1120684"},{"key":"2026071215474082337_j_raon-2025-0034_ref_021","doi-asserted-by":"crossref","unstructured":"Li Y, Pan C, Gao Y, Zhang L, Ji D, Cui X, et al. Total neoadjuvant therapy with PD-1 blockade for high-risk proficient mismatch repair rectal cancer. JAMA Surg 2024; 159: 529-37. doi: 10.1001\/jamasurg.2023.7996","DOI":"10.1001\/jamasurg.2023.7996"},{"key":"2026071215474082337_j_raon-2025-0034_ref_022","doi-asserted-by":"crossref","unstructured":"Grossman SA, Ellsworth S, Campian J, Wild AT, Herman JM, Laheru D, et al. Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors. J Natl Compr Canc Netw 2015; 13: 1225-31. doi: 10.6004\/jnccn.2015.0151","DOI":"10.6004\/jnccn.2015.0151"},{"key":"2026071215474082337_j_raon-2025-0034_ref_023","doi-asserted-by":"crossref","unstructured":"Huang W, Dang J, Li Y, Cui HX, Lu WL, Jiang QF. Effect of pelvic bone marrow sparing intensity modulated radiation therapy on acute hematologic toxicity in rectal cancer patients undergoing chemo-radiotherapy. Front Oncol 2021; 11: 646211. doi: 10.3389\/fonc.2021.646211","DOI":"10.3389\/fonc.2021.646211"},{"key":"2026071215474082337_j_raon-2025-0034_ref_024","doi-asserted-by":"crossref","unstructured":"Mahantshetty U, Krishnatry R, Chaudhari S, Kanaujia A, Engineer R, Chopra S, et al. Comparison of 2 contouring methods of bone marrow on CT and correlation with hematological toxicities in non-bone marrowsparing pelvic intensity-modulated radiotherapy with concurrent cisplatin for cervical cancer. Int J Gynecol Cancer 2012; 22: 1427-34. doi: 10.1097\/IGC.0b013e3182664b46","DOI":"10.1097\/IGC.0b013e3182664b46"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2025-0034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T22:57:49Z","timestamp":1783897069000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2025-0034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6,16]]},"published-print":{"date-parts":[[2025,6,1]]}},"alternative-id":["10.2478\/raon-2025-0034"],"URL":"https:\/\/doi.org\/10.2478\/raon-2025-0034","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}